165 related articles for article (PubMed ID: 15970067)
1. Doxazosin versus bendrofluazide: a comparison of the metabolic effects in British South Asians with hypertension.
Hobbs FR; Khan T; Collins B
Br J Gen Pract; 2005 Jun; 55(515):437-43. PubMed ID: 15970067
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
[TBL] [Abstract][Full Text] [Related]
3. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
JAMA; 2000 Apr; 283(15):1967-75. PubMed ID: 10789664
[TBL] [Abstract][Full Text] [Related]
4. A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk.
Daae LN; Westlie L
Blood Press; 1998 Jan; 7(1):39-45. PubMed ID: 9551876
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients.
Talseth T; Westlie L; Daae L; Vatle S
Am Heart J; 1988 Dec; 116(6 Pt 2):1790-6. PubMed ID: 2904752
[TBL] [Abstract][Full Text] [Related]
6. Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension.
Frick MH; Cox DA; Himanen P; Huttunen M; Pitkäjärvi T; Pörsti P; Pöyhönen L; Pyykönen ML; Reinikainen P; Salmela P
Am J Cardiol; 1987 May; 59(14):61G-67G. PubMed ID: 2884854
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M
Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of doxazosin versus atenolol in mild-to-moderate hypertension.
Giorgi G; Legramante JM; Fioravanti G; Paies G; Legramante A
Am Heart J; 1988 Dec; 116(6 Pt 2):1801-5. PubMed ID: 2904754
[TBL] [Abstract][Full Text] [Related]
9. A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension.
Nash DT; Schonfeld G; Reeves RL; Black H; Weidler DJ
Am J Cardiol; 1987 May; 59(14):87G-90G. PubMed ID: 2884859
[TBL] [Abstract][Full Text] [Related]
10. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group
Hypertension; 2003 Sep; 42(3):239-46. PubMed ID: 12925554
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of doxazosin versus enalapril in the treatment of patients with mild-to-moderate hypertension.
Tan KW; Frise SA
Clin Ther; 1997; 19(3):459-70. PubMed ID: 9220210
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive and metabolic effects of doxazosin in hypertensive patients with concomitant non-insulin-dependent diabetes mellitus.
Inoue Y; Kaku K; Kaneko T; Matsumura S; Nakayama H; Yoshizaki Y; Ando S; Inoue M; Hatao M
J Int Med Res; 1996; 24(1):138-46. PubMed ID: 8674792
[TBL] [Abstract][Full Text] [Related]
13. An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.
Torvik D; Madsbu HP
Am J Cardiol; 1987 May; 59(14):68G-72G. PubMed ID: 2884855
[TBL] [Abstract][Full Text] [Related]
14. Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension.
Pool JL
Am J Cardiol; 1987 May; 59(14):46G-50G. PubMed ID: 2884853
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of doxazosin and atenolol on serum lipids and blood pressure in hypertensive smokers.
Talseth T; Westlie L; Daae LN
J Hypertens Suppl; 1990 Sep; 8(5):S47-51. PubMed ID: 1981077
[TBL] [Abstract][Full Text] [Related]
16. Clinical usefulness of doxazosin in patients with type 2 diabetes complicated by hypertension: effects on glucose and lipid metabolism.
Inukai T; Inukai Y; Matsutomo R; Okumura K; Takanashi K; Takebayashi K; Tayama K; Aso Y; Takemura Y
J Int Med Res; 2004; 32(2):206-13. PubMed ID: 15080025
[TBL] [Abstract][Full Text] [Related]
17. Selective alpha 1 inhibition with doxazosin in hypertensive smokers and non-smokers: haemodynamic and metabolic effects.
Westheim A; Daae LN; Kierulf P; Brusletto B; Holme I; Syvertsen JO
J Hypertens Suppl; 1990 Sep; 8(5):S41-6. PubMed ID: 1981076
[TBL] [Abstract][Full Text] [Related]
18. Doxazosin: a new alpha 1-adrenergic antagonist.
Babamoto KS; Hirokawa WT
Clin Pharm; 1992 May; 11(5):415-27. PubMed ID: 1349855
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience with doxazosin in general medical practice.
Rosenthal J
Am Heart J; 1988 Dec; 116(6 Pt 2):1748-57. PubMed ID: 2904745
[TBL] [Abstract][Full Text] [Related]
20. [Doxazosin in the treatment of light-to-moderate arterial hypertension in a non-comparative multicenter study].
Pessina AC
Clin Ter; 1995 Jan; 146(1):3-12. PubMed ID: 7705011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
